×
About 639 results

ALLMedicine™ Protoporphyria Center

Research & Reviews  303 results

Erythropoietic Protoporphyria.
https://doi.org/10.1177/12034754211016295
Journal of Cutaneous Medicine and Surgery; Liu ZH, Shen H

May 4th, 2021 - Erythropoietic Protoporphyria.|2021|Liu ZH,Shen H,|

Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria.
https://doi.org/10.1080/17512433.2021.1879638
Expert Review of Clinical Pharmacology; Wensink D, Wagenmakers MAEM et. al.

Jan 28th, 2021 - Introduction: In erythropoietic protoporphyria (EPP), an inherited disorder of heme biosynthesis, accumulation of protoporphyrin IX results in acute phototoxicity. EPP patients experience severe burning pain after light exposure, which results in ...

Hematopoietic cell transplant for reversal of liver fibrosis in a pediatric patient wit...
https://doi.org/10.1111/petr.13966
Pediatric Transplantation REFERENCES; Hashmi SK, Harstead E et. al.

Jan 6th, 2021 - EPP is a rare disorder of heme biosynthesis in which patients present with disabling photosensitivity. A subset of patients develop severe liver disease with progressive liver failure necessitating an OLT. A HCT can potentially cure EPP by replaci...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  317 results

Erythropoietic Protoporphyria.
https://doi.org/10.1177/12034754211016295
Journal of Cutaneous Medicine and Surgery; Liu ZH, Shen H

May 4th, 2021 - Erythropoietic Protoporphyria.|2021|Liu ZH,Shen H,|

Scenesse - afamelanotide implant-CSM Clinical Supplies Management Europe GmbH
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1533405-cdca-5ece-e053-2a95a90a90c5

Mar 11th, 2021 - SCENESSE® is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). SCENESSE is a melanocortin 1 receptor (MC1-R) agonist indicated to increase pain free li...

Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria.
https://doi.org/10.1080/17512433.2021.1879638
Expert Review of Clinical Pharmacology; Wensink D, Wagenmakers MAEM et. al.

Jan 28th, 2021 - Introduction: In erythropoietic protoporphyria (EPP), an inherited disorder of heme biosynthesis, accumulation of protoporphyrin IX results in acute phototoxicity. EPP patients experience severe burning pain after light exposure, which results in ...

see more →

News  17 results

Novel Oral Drug Improves Sunlight Tolerance in Patients With Erythropoietic Protoporphyria
https://www.medscape.com/viewarticle/936274

Aug 24th, 2020 - Dersimelagon, a novel once-daily oral selective melanocortin-1 receptor agonist, significantly boosted sunlight tolerance in patients with erythropoietic protoporphyria in a multicenter, phase 2, randomized trial, Kirstine Belongie, PhD, reported ...

FDA approves afamelanotide for treatment of rare condition with light-induced pain
https://www.mdedge.com/fedprac/article/209685/rare-diseases/fda-approves-afamelanotide-treatment-rare-condition-light?channel=268
Christopher Palmer

Oct 8th, 2019 - The Food and Drug Administration has approved afamelanotide (Scenesse) to “increase pain-free light exposure” in adults with a history of phototoxic reactions from erythropoietic protoporphyria, a rare condition that causes extremely painful react.

FDA OKs New Treatment Afamelanotide for Phototoxic Reactions
https://www.medscape.com/viewarticle/919622

Oct 7th, 2019 - The US Food and Drug Administration (FDA) has approved afamelanotide (Scenesse, Clinuvel), the first treatment to ease phototoxic reactions in patients with erythropoietic protoporphyria, according to an agency news release. Erythropoietic protopo...

Team identifies mutation that causes EPP
https://www.mdedge.com/hematology-oncology/article/185441/anemia/team-identifies-mutation-causes-epp
HT Staff

Sep 10th, 2017 - Red blood cells Researchers say they have discovered a genetic mutation that triggers erythropoietic protoporphyria (EPP). The team performed genetic sequencing on members of a family from Northern France who had EPP of a previously unknown geneti.

FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder
http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-increase-pain-free-light-exposure-patients-rare-disorder

For Immediate Release: October 08, 2019 The U.S. Food and Drug Administration today granted approval to Scenesse (afamelanotide) to increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from er...

see more →